| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Escitalopram was launched as Cipralex in Switzerland, Sweden and UK for the treatment of depression and panic disorder. It is the S-enantiomer version of the selective serotonin reuptake inhibitor (SSRI) citalopram approved in 1989. It can be obtained from 5cyanophthalide by successive reactions with 4-fluorophenyl magnesium bromide and 3-(dimethylamino)propyl magnesium chloride. The resulting racemic diol can be resolved by several routes such as crystallization with a chiral acid. Finally, a two step cyclisation procedure affords escitalopram. Escitalopram is twice as effective as the racemate and over 100 fold more potent than the R-enantiomer in inhibiting the 5HT reuptake in vivo in rat brain synaptosomes. Moreover, it exhibits higher selectivity for the human serotonin transporter relative to the noradrenaline or dopamine transporters than any other currently available SSRl's. In the mouse forced swim test, the duration of immobility (which reflects antidepressant activity) for escitalopram was comparable to citalopram and greater than (R)-citalopram. Clinical trials in patients with panic disorders or depression have shown that escitalopram has a clinically relevant and significant effect.
|
Items
|
Specifications
|
Results
|
|
Appearance
|
White Powder |
Confirm
|
|
Odor& Taste
|
Characteristic
|
Confirm
|
|
Loss on drying
|
≤8.0%
|
2.8%
|
|
Assay(HPLC)
|
99.0% min
|
99.2%
|
|
Ash
|
≤1.0%
|
0.35%
|
|
Heavy Metal
|
≤10 ppm
|
Confirm
|
|
As
|
≤1.0ppm
|
Confirm
|
|
Pb
|
≤1.0ppm
|
Confirm
|
|
Cd
|
≤1.0ppm
|
Confirm
|
|
Hg
|
≤0.1ppm
|
Confirm
|
|
Total plate count
|
≤1000 cfu/g
|
Confirms
|
|
Yeast&Mold
|
≤100 cfu/g
|
Confirms
|
|
E.Coli
|
Negative
|
Negative
|
|
Salmonella
|
Negative
|
Negative
|
|
Staphylococcus aureus
|
Negative
|
Negative
|
){kind=link}